Neurodegenerative diseases, such as Alzheimer's disease, comprise some of our major public health problems and affect millions of people worldwide. Despite significant efforts, there is still a lack of effective drugs to prevent or cure these diseases. The aim of our project proposal is to investigate whether a particular type of molecule can be used to stop the progression of Alzheimer's disease. Step 1 when developing a drug is to choose a target to which the drug will be directed. The targets we have chosen are two proteins, A-beta and tau, which occur in various forms of deposits (aggregates) in the brain in Alzheimer's disease. Several studies have shown that these aggregates spread between nerve cells and that the aggregates affect the function of the cells, leading to nerve cell death. In the project, we will produce molecules that selectively find A-beta or tau aggregates and the molecules will then be tested in different fruit fly models to see how they affect the spread and induced cell death of A-beta and tau aggregates. The overall goal of the project is to show that tailored molecules can selectively affect the negative effects of A-beta and tau aggregates. In the long run, the progress of the project may lead to a new generation of drugs that could be used to prevent the underlying disease process in Alzheimer's disease and other similar neurodegenerative diseases.